Literature DB >> 18410284

Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication.

Mie Ando1, Masaaki Korenaga, Keisuke Hino, Masanori Ikeda, Nobuyuki Kato, Sohji Nishina, Isao Hidaka, Isao Sakaida.   

Abstract

BACKGROUND/AIM: Hepatitis C virus (HCV) core protein has been shown to inhibit mitochondrial electron transport and to increase reactive oxygen species (ROS) in vitro and in vivo. The aim of this study was to investigate whether inhibiting HCV replication could restore the mitochondrial redox state and electron transport activity.
METHODS: We measured ROS, mitochondrial reduced glutathione content, and mitochondrial complex I, II, III and IV activities and protein expression in full genomic HCV replicon cells and cured cells that had been prepared by eliminating HCV RNA from replicon cells by interferon (IFN)-alpha treatment.
RESULTS: Cured cells had significantly lower ROS production and greater mitochondrial glutathione content than replicon cells. Complete inhibition of HCV replication by IFN-alpha restored complex I and IV activities by 20-30% (P<0.01) and complex I expression (P<0.05). Treatment with fluvastatin, one of the 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors, which is known to have anti-HCV activity, partially inhibited core protein expression and restored complex I activity in full genomic HCV replicon cells to a lesser degree (P<0.05).
CONCLUSIONS: Our results show that the mitochondrial redox state and electron transport activity can be restored by reducing HCV replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410284     DOI: 10.1111/j.1478-3231.2008.01720.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.

Authors:  Donna N Douglas; Christopher Hao Pu; Jamie T Lewis; Rakesh Bhat; Anwar Anwar-Mohamed; Michael Logan; Garry Lund; William R Addison; Richard Lehner; Norman M Kneteman
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

2.  Interactions Between Hepatitis C Virus and Mitochondria: Impact on Pathogenesis and Innate Immunity.

Authors:  Ting Wang; Steven A Weinman
Journal:  Curr Pathobiol Rep       Date:  2013-09

3.  Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin.

Authors:  Sandra Pisonero-Vaquero; María V García-Mediavilla; Francisco Jorquera; Pedro L Majano; Marta Benet; Ramiro Jover; Javier González-Gallego; Sonia Sánchez-Campos
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

Review 4.  Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections.

Authors:  Changbo Qu; Shaoshi Zhang; Yang Li; Yijin Wang; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Rev Med Virol       Date:  2019-07-19       Impact factor: 6.989

Review 5.  HCV and oxidative stress in the liver.

Authors:  Alexander V Ivanov; Birke Bartosch; Olga A Smirnova; Maria G Isaguliants; Sergey N Kochetkov
Journal:  Viruses       Date:  2013-01-28       Impact factor: 5.048

6.  Hepatitis C virus induces the mitochondrial translocation of Parkin and subsequent mitophagy.

Authors:  Seong-Jun Kim; Gulam H Syed; Aleem Siddiqui
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

7.  Localization of HPV-18 E2 at mitochondrial membranes induces ROS release and modulates host cell metabolism.

Authors:  Deborah Lai; Chye Ling Tan; Jayantha Gunaratne; Ling Shih Quek; Wenlong Nei; Françoise Thierry; Sophie Bellanger
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

Review 8.  Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.

Authors:  Mario Arciello; Manuele Gori; Clara Balsano
Journal:  Oxid Med Cell Longev       Date:  2013-11-24       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.